Clarivate (CLVT) Q4 2024 earnings summary

Executive summary

• 2024 results showed a strong product foundation but highlighted the need for improved organic growth, prompting a Value Creation Plan (VCP) and a strategic review focused on portfolio optimization, recurring revenue, and AI-driven innovation.

• The VCP targets revenue optimization, sales execution, innovation, cost rationalization, and portfolio rationalization, including leadership changes and enhanced customer engagement.

• Strategic alternatives, including divestitures of business units or segments, are being evaluated to unlock value and maximize shareholder returns.

• Transitioning transactional businesses to subscription models is a key initiative, especially in academia, government, and life sciences.

• $200M in share repurchases and $198M in debt prepayment executed in 2024, with a new $500M repurchase program authorized.

Financial highlights

• Q4 2024 revenue was $663 million, down $21 million year-over-year; full year revenue was $2.56 billion, down $72 million, mainly due to divestitures.

• Q4 net loss improved to $191.8 million from $863 million in Q4 2023; full year net loss improved to $636.7 million from $911 million.

• Adjusted diluted EPS was $0.21 in Q4 and $0.73 for the year, both down year-over-year but within original guidance.

• Operating cash flow for the year was $647 million; free cash flow was $358 million, down 28.7% year-over-year.

• Organic revenue declined 1.4% for the year, driven by a 6.5% drop in transactional business; organic subscription revenue grew 0.9%.

Outlook and guidance

• 2025 revenue guidance is $2.28 billion to $2.40 billion, reflecting continued transactional revenue declines and strategic disposals.

• Recurring revenue mix projected to rise to 85–87%, improving predictability and margins; recurring organic growth expected to be flat to +1%.

• Adjusted EBITDA expected between $940 million and $1 billion, with profit margin maintained at 41.5%.

• Diluted adjusted EPS forecasted at $0.60–$0.70; free cash flow anticipated at $300 million–$380 million.

• Organic ACV growth expected to accelerate to 1.5% at midpoint.